Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

SIMPLE SUMMARY: Monoclonal antibody (mAb) therapy has been an important addition to the therapeutic arsenal in B-cell malignancies. MAbs can induce cytotoxicity against B-cell malignancies by antibody effector functions mediated via their fragment crystallizable (Fc) region. In order to enhance the...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Horst, Hilma J., Nijhof, Inger S., Mutis, Tuna, Chamuleau, Martine E. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603375/
https://www.ncbi.nlm.nih.gov/pubmed/33086644
http://dx.doi.org/10.3390/cancers12103041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603375/
https://www.ncbi.nlm.nih.gov/pubmed/33086644
http://dx.doi.org/10.3390/cancers12103041

Ejemplares similares